Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous upper airway disease with multiple etiologies. Clinically, CRSwNP can be classified into either eosinophilic or non-eosinophilic subtypes. The eosinophilic phenotype of CRSwNP is widely thought to be highly associated with recurrence of nasal polyps or surgical failure. Epithelial cells have a crucial role in the development of Th2-biased airway diseases. Recent studies have shown that a wide range of external stimuli such as allergens and microorganisms can elicit the release of epithelial-derived Th2-driving cytokines and chemokines. Protease activity is a feature common to these multiple environmental insults and there is growing evidence for the concept that an imbalance of proteases and protease inhibitors in the epithelial barrier leads to both the initiation and maintenance of chronic eosinophilic airway inflammation. In this review, we analyze recent work on the role of proteases in the development of the sinonasal mucosal type 2 immune response with an emphasis on the molecular pathways promoting adaptive Th2 cell immunity.
Introduction
Chronic rhinosinusitis is a chronic inflammatory upper airway disease characterized by 12 weeks of typical symptoms including nasal discharge, congestion, facial pressure or pain, and olfactory disorder (Fokkens et al., 2012). Chronic rhinosinusitis with nasal polyps (CRSwNP), a multifactorial and highly heterogeneous upper airway disease, is a severe phenotype of chronic rhinosinusitis and presents with distinct immunological and histopathological features compared with chronic rhinosinusitis without nasal polyps (CRSsNP).
Despite aggressive medical therapy or radical endoscopic sinus surgical treatment, many patients with CRSwNP tend to be poorly controlled and have a high recurrence rate (Wynn and Har-El, 2004; Mendelsohn et al., 2011; Baguley et al., 2014; DeConde et al., 2017). Several factors which associate with a worse outcome or recurrence risk have been identified, such as high tissue eosinophil infiltration, more severe preoperative disease (i.e., a higher CT score), and a series of comorbid disease (i.e., aspirin-exacerbated respiratory disease (AERD), allergic asthma and cystic fibrosis) (Desrosiers, 2004; Tosun et al., 2010; Mortuaire et al., 2015; Ta and White, 2015; Tipirneni and Woodworth, 2017; Wu et al., 2017).
Clinically, CRSwNP is classified into two phenotypes based on the dominant inflammatory cell type in tissues: eosinophilic CRSwNP (ECRSwNP) and non-eosinophilic CRSwNP (NECRSwNP) (Cao et al., 2009; Shah et al., 2016; Wu et al., 2016; Cho S.-W. et al., 2017). In western countries, the majority of patients with CRSwNP (80–88%) have prominent tissue eosinophilia, edema formation, and a type 2 helper T-cell (Th2) dominant immune response (Bateman et al., 2005; Fokkens et al., 2005; Van Zele et al., 2006). CRSwNP may be associated with asthma and aspirin intolerance (Fokkens et al., 2012; Stevens et al., 2017). However, at least half of patients with CRSwNP in East Asian countries including China, Korea and Japan have a non-eosinophilic phenotyps of nasal polyps characterized by Th1/Th17-dominant inflammation (Kim et al., 2007; Zhang et al., 2008; Cao et al., 2009; Ikeda et al., 2013).
The past decade has witnessed a change in the understanding of mechanisms underlying eosinophilic airway diseases from a paradigm in which allergen-independent, e.g., Th2 cells are the primary drivers, to one in which production of epithelial-derived chemokines and cytokines by dysfunctional respiratory epithelium are the primary orchestrators of the eosinophilic immune response (Hammad and Lambrecht, 2015; Pfeffer and Corrigan, 2017). A large range of both endogenous and extrinsic stimuli can activate the epithelial cell and elicit the release of epithelial-derived chemokines and cytokines which, in turn, induce the type 2 immune response (Hammad and Lambrecht, 2015; Schleimer and Berdnikovs, 2017). External stimuli, including allergen, fungus, Staphylococcus aureus and microbiome disturbance have been posited as significant contributing factors in CRSwNP pathophysiology and have been implicated in driving Th2-biased airway disease (Sachse et al., 2010; Clark et al., 2013; Madeo and Frieri, 2013; Ou et al., 2014; Lan et al., 2016; Orlandi et al., 2016; Tomassen et al., 2016; Schleimer, 2017).
Protease activity is a common unifying feature of many of these environmental insults suggesting an underlying common etiopathogenesis (Sokol et al., 2008; Gregory and Lloyd, 2011; Stentzel et al., 2017; Teufelberger et al., 2017). Airborn allergens, such mites, pollen, as well as microorganisms, such as bacteria, rhinovirus, and influenza virus, and fungi are major sources of exogenous proteases (Reed and Kita, 2004; Sokol et al., 2008; Costenaro et al., 2011; Takai and Ikeda, 2011; Kesic et al., 2012). The innate immune response to these exogenous proteases seems to play a crucial role during the development of Th2-biased immune response (Kamijo et al., 2013; Hara et al., 2014; Snelgrove et al., 2014; Teufelberger et al., 2017). It therefore follows that an imbalance of proteases and protease inhibitors in the epithelial barrier may lead to the initiation and maintainancc of eosinophilic inflammation in CRSwNP and therefore be a central driver of eosinophilic airway disease (Kouzaki et al., 2017; Pfeffer and Corrigan, 2017).
This review will summarize the current knowledge on the role of proteases during the development of the sinonasal mucosal type 2 immune response, with an emphasis on the molecular pathways initiating the innate type 2 cell response and then promoting adaptive Th2 cell immunity. This is followed by a discussion of the dysfunctional regulation of proteases and proteases inhibitors in the epithelial barrier.
Mechanisms of the activation of the airway epithelial cells upon external protease exposure
Cysteine and or serine proteases occur in some groups of airborne mite, pollen, cockroach, fungi, and Staphylococcus aureus (Asokananthan et al., 2002; Reed and Kita, 2004; Jacquet, 2011; Takai and Ikeda, 2011; Balenga et al., 2015; Kale et al., 2017; Stentzel et al., 2017; Teufelberger et al., 2017). Allergen derived proteases interact with epithelial cells through three principle pathways: direct effects on junctional proteins, reacting with cell surface protease-activated receptors (PARs), and toll-like receptor 4 (TLR4)-dependent epithelial activation. An integrated mechanism is summarized and illustrated in Figure 1.
Figure 1
Allergen source-derived proteases (both cysteine and serine protease) can directly degrade tight junctions in the epithelium (Wan et al., 1999, 2001; Tai et al., 2006; Runswick et al., 2007; Hirasawa, 2010; Kale et al., 2017) and increase the accessibility of microorganisms and antigens to the underlying lamina propria and connective tissue thereby triggering strong innate immune responses to allergens (Gregory and Lloyd, 2011). It has been reported that the levels of occludin, E-cadherin, and zonula occludens-1 (ZO-1) were all reduced in mature polyps derived from patients with CRSwNP. Moreover, aquaporin 5, a marker of epithelial differentiation, was obviously reduced in sinonasal samples of patients with CRSwNP when compared with levels in CRSsNP or control subjects (Shikani et al., 2014).
Apart from direct effects on junctional epithelial proteins, environmental proteases can interact with PARs in the airway to stimulate the proliferation and migration of innate and adaptive leukocytes (Reed and Kita, 2004). PARs are a novel family of seven-transmembrane G protein-coupled receptors that are widely expressed in human airway epithelium. There are four types of PARs (PAR1, PAR2, PAR3, and PAR4) which play an integral role in defending against environmental proteases (Coughlin and Camerer, 2003; Reed and Kita, 2004). Several reports have linked PAR activation to the allergic immune response (Kheradmand et al., 2002; Jacquet, 2011). Exogenous proteases from house dust mite (HDM), cockroach or Alternaria alternate were shown to play an important role in allergy development, partly by activating PAR-2 signaling in the epithelial cells (de Boer et al., 2014). In CRSwNP, airborne fungal proteases can activate both PAR-2 and PAR-3 leading to the proliferation and migration of inflammatory cells (Shin et al., 2006). Furthermore, the level of the PAR-2 in cultured primary nasal epithelial cells and nasal polyps from patients with ECRSwNP was significantly increased as compared with NECRSwNP and controls (Kouzaki et al., 2016). However, in patients with allergic fungal rhinosinusitis, only PAR-3 showed statistically significant differential expression compared to non-diseased controls (Ebert et al., 2014).
Staphylococcus aureus is a versatile bacteria frequently found colonizing patients with Th2-biased diseases such CRSwNP and asthma (Bachert et al., 2010; Sachse et al., 2010). Several endotypes of chronic rhinosinusitis have been identified based on the presence of S. aureus enterotoxin(SE)- specific IgE (Bachert and Akdis, 2016; Tomassen et al., 2016). The presence of SE-specific IgE associates with intense eosinophilic inflammation in CRSwNP, high IgE concentration and comorbid asthma (Bachert et al., 2010; Tomassen et al., 2016). Recently, serine protease like protein D (SplD) and other closely related proteases secreted by S. aureus have been identified as inducers of allergic asthma in both humans and mice (Stentzel et al., 2017). Furthermore, SplD-induced Th2-biased inflammatory response and IgE production in the airway inflammation were largely dependent on the IL-33/ST2 axis and independent of TLR4 and PAR-2 signaling (Teufelberger et al., 2017).
TLR activation has been the subject of intense study with respect to its role in protease mediated airway inflammation. The coagulation system has been implicated in eosinophilic airway diseases, such as asthma and CRSwNP as a result of collagen deposition and airway remodeling, (Shimizu et al., 2011; Lambrecht and Hammad, 2013; Kim et al., 2015). Millien et al. found that activation of the coagulation cascade by allergen-derived proteases is an important factor promoting asthma-like changes in mice. Allergen proteases can cleave the serum factor fibrinogen, thus releasing FCPs which directly activate TLR4 signaling (Millien et al., 2013). The development of an asthma-like condition caused by house-dust mites challenge relies on the expression of TLR4 on lower airway epithelial cells (Hammad et al., 2009). Furthermore, thrombin, the classic activator of coagulation, can also cleave fibrinogen into FCPs resulting in further upregulation of the TLR4 pathway. A recent study identifies a programmed cell death 1 ligand 2+ (PD-L2+) DC phenotype which accounts for the induction of Th2 cell response upon protease allergens exposure and fibrinogen-cleavage products can promote the generation of PD-L2+ DC through TLR4 (Cho M. et al., 2017). These studies suggest that TLR4 plays a critical role in the allergic response upon exposure to exogenous proteases.
A study by Seung-Heon Shin et al. showed that airborne fungi induced the activation of nasal polyp epithelial cell and TLR expression (TLR2, TLR3 and TLR4). Cytokine production was, in turn, suppressed by protease inhibitors and anti-TLR4 antibodies (Shin and Lee, 2010).
Imbalance and dysfunctional regulation of proteases and proteases inhibitors in the epithelial barrier of CRSwNP
Recently, a study showed that an imbalance of proteases and protease inhibitors within the epithelial barrier contributes to the pathogenesis of eosinophilic chronic rhinosinusitis (Kouzaki et al., 2017). Barrier defects might be induced by damage to key proteins that comprise tight or adherent junctions secondary to increased or unopposed protease activity. These findings suggest that individual susceptibility to protease mediated inflammation may arise from the inability to adequately mitigate exogenous protease mediated epithelial damage. A recent review (Schleimer and Berdnikovs, 2017) suggested that cystatin A and SPINK5 (a cysteine and serine protease inhibitor, respectively) possess important roles in protecting the airway epithelium against environmental proteases. Furthermore, SPINK5 can protect PARs which are expressed on multiple cell types in the nasal epithelium from environmental proteases (Hershenson, 2007). Furthermore, SPINK5 is thought to regulate the function of numerous proteases that might compromise the barrier (Tieu et al., 2009). What's more, both human and animal studies have showed that SPINK5 mutations are associated with chronic inflammation in epithelium (Cookson, 2004; Moffatt, 2004).
P-glycoprotein (P-gp) has been reported as a key immunoregulator of eosinophilic inflammation in both CRSwNP and CRSsNP (Bleier et al., 2013; Feldman et al., 2013; Cheng and Bleier, 2016). Protease inhibitors have been reported to induce the expression of P-gp suggesting that an imbalance in the protease system may further exacerbate inflammation through the induction of P-gp expression(Perloff et al., 2000; Huang et al., 2001; Chandler et al., 2003; Zastre et al., 2009). Additionally, some protease inhibitors have been shown to function as P-gp substrates further strengthening the link between protease inhibitors and P-gp (Chaillou et al., 2002; Meaden et al., 2002) (Zhang and Benet, 1998). While disequilibrium of both P-gp expression and proteases inhibitors within the nasal mucosa may play an interrelated role in CRSwNP, further studies are needed to explore this possible function.
Summary and perspectives
In patients with CRSwNP, exogenous allergen and microorganism derived proteases play a crucial role in the development of type 2 immune response at the mucosal surface. Through direct effects on junctional proteins, binding to cell surface PARs, TLR4-dependent epithelial activation, disruption of barrier function, and P-gp activation, proteases both initiate and maintain the inflammation characteristic of Th2 mucosal disease. It has been proposed that drugs targeting protease function (Verma et al., 2016) in nasal mucus to restore the balance between proteases and protease inhibitors (Pfeffer and Corrigan, 2017) may represent an important potential therapeutic strategy in patients with CRSwNP and other eosinophilic airway diseases. However, more studies are required to explore the exact role of the protease and protease inhibitor axis in CRSwNP.
Statements
Author contributions
DW drafted the manuscript. Both YW and BB reviewed the manuscript and provided revisions.
Conflict of interest
The senior author has a patent related to P-gp modulation in CRSwNP. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- CRSwNP
Chronic rhinosinusitis with nasal polyps
- CRSsNP
chronic rhinosinusitis without nasal polyps
- ECRSwNP
eosinophilic chronic rhinosinusitis with nasal polyps
- NECRSwNP
non-eosinophilic chronic rhinosinusitis with nasal polyps
- Th2
type 2 helper T-cell
- PARs
protease-activated receptors
- TLR4
toll-like receptor 4
- ZO-1
Zonula occludens-1
- HDM
house dust mite
- SpID
serine protease like protein D
- FCPs
fibrinogen cleavage products
- P-gp
P-glycoprotein.
Abbreviations
References
1
AsokananthanN.GrahamP. T.StewartD. J.BakkerA. J.EidneK. A.ThompsonP. J.et al. (2002). House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. J. Immunol. 169, 4572–4578. 10.4049/jimmunol.169.8.4572
2
BachertC.AkdisC. A. (2016). Phenotypes and emerging endotypes of chronic rhinosinusitis. J. Allergy Clin. Immunol. Pract. 4, 621–628. 10.1016/j.jaip.2016.05.004
3
BachertC.ZhangN.HoltappelsG.De LobelL.van CauwenbergeP.LiuS.et al. (2010). Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J. Allergy Clin. Immunol. 126, 962–968.e6. 10.1016/j.jaci.2010.07.007
4
BaguleyC.BrownlowA.YeungK.PrattE.SacksR.HarveyR. (2014). The fate of chronic rhinosinusitis sufferers after maximal medical therapy. Int. Forum Allergy Rhinol. 4, 525–532. 10.1002/alr.21315
5
BalengaN. A.KlichinskyM.XieZ.ChanE. C.ZhaoM.JudeJ.et al. (2015). A fungal protease allergen provokes airway hyperresponsiveness in asthma. Nat. Commun. 6:6763. 10.1038/ncomms7763
6
BatemanN.ShahiA.FeeleyK. M.WoolfordT. J. (2005). Activated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patients. Clin. Otolaryngol. 30, 221–225. 10.1111/j.1365-2273.2005.00969.x
7
BleierB. S.NoceraA. L.IqbalH.HoangJ. D.FeldmanR. E.HanX. (2013). P-glycoprotein functions as an immunomodulator in healthy human primary nasal epithelial cells. Int. Forum Allergy Rhinol. 433–438. 10.1002/alr.21166
8
CaoP.-P.LiH. B.WangB. F.WangS. B.YouX. J.CuiY. H.et al. (2009). Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J. Allergy Clin. Immunol. 124, 478–484.e2. 10.1016/j.jaci.2009.05.017
9
ChaillouS.DurantJ.GarraffoR.GeorgenthumE.RoptinC.ClevenberghP.et al. (2002). Intracellular concentration of protease inhibitors in HIV-1–infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin. Trials3, 493–501. 10.1310/0873-BVDP-AKAY-445U
10
ChandlerB.AlmondL.FordJ.OwenA.HoggardP.KhooS.et al. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. Acquir. Immune Defic. Syndr. 33, 551–556. 10.1097/00126334-200308150-00001
11
ChengY. S.BleierB. S. (2016). Influence of P-glycoprotein function on chronic rhinosinusitis/nasal polyps pathophysiology. Adv. Otorhinolaryngol. 79, 38–47. 10.1159/000445094
12
ChoM.LeeJ. E.LimH.ShinH. W.KhalmuratovaR.ChoiG.et al. (2017). Fibrinogen cleavage products and Toll-like receptor 4 promote the generation of programmed cell death 1 ligand 2-positive dendritic cells in allergic asthma. J. Allergy Clin. Immunol. [Epub ahead of print]. 10.1016/j.jaci.2017.09.019
13
ChoS.-W.KimD. W.KimJ. W.LeeC. H.RheeC. S. (2017). Classification of chronic rhinosinusitis according to a nasal polyp and tissue eosinophilia: limitation of current classification system for Asian population. Asia Pac. Allergy7:121. 10.5415/apallergy.2017.7.3.121
14
ClarkD. W.WenaasA.LuongA.CitardiM. J.FakhriS. (2013). Staphylococcus aureus prevalence in allergic fungal rhinosinusitis vs other subsets of chronic rhinosinusitis with nasal polyps. Int. Forum Allergy Rhinol. 3, 89–93. 10.1002/alr.21090
15
CooksonW. (2004). The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat. Rev. Immunol. 4, 978–988. 10.1038/nri1500
16
CostenaroL.KaczmarskaZ.ArnanC.JanowskiR.CoutardB.Solà M.et al. (2011). Structural basis for antiviral inhibition of the main protease, 3C, from human enterovirus 93. J. Virol. 85, 10764–10773. 10.1128/JVI.05062-11
17
CoughlinS. R.CamererE. (2003). Participation in inflammation. J. Clin. Invest. 111, 25–27. 10.1172/JCI17564
18
de BoerJ. D.van't VeerC.StrooI.van der MeerA. J.de VosA. F.van der ZeeJ. S.et al. (2014). Protease-activated receptor-2 deficient mice have reduced house dust mite-evoked allergic lung inflammation. Innate Immun. 20, 618–625. 10.1177/1753425913503387
19
DeCondeA. S.MaceJ. C.LevyJ. M.RudmikL.AltJ. A.SmithT. L. (2017). Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope127, 550–555. 10.1002/lary.26391
20
DesrosiersM. (2004). Refractory chronic rhinosinusitis: pathophysiology and management of chronic rhinosinusitis persisting after endoscopic sinus surgery. Curr. Allergy Asthma Rep. 4, 200–207. 10.1007/s11882-004-0027-z
21
EbertC. S.McKinneyK. A.UrrutiaG.WuM.RoseA. S.FleischmanG. M.et al. (2014). Expression of protease-activated receptors in allergic fungal rhinosinusitis. Int. Forum Allergy Rhinol. 4, 266–271. 10.1002/alr.21295
22
FeldmanR. E.LamA. C.SadowP. M.BleierB. S. (2013). P-glycoprotein is a marker of tissue eosinophilia and radiographic inflammation in chronic rhinosinusitis without nasal polyps. Int. Forum Allergy Rhinol. 3, 684–687. 10.1002/alr.21176
23
FokkensW. J.LundV. J.MullolJ.BachertC.AlobidI.BaroodyF.et al. (2012). EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology50, 1–12. 10.4193/Rhino50E2
24
FokkensW.LundV.BachertC.ClementP.HelllingsP.HolmstromM.et al. (2005). EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy60, 583–601. 10.1111/j.1398-9995.2005.00830.x
25
GregoryL. G.LloydC. M. (2011). Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 32, 402–411. 10.1016/j.it.2011.06.006
26
HammadH.ChieppaM.PerrosF.WillartM. A.GermainR. N.LambrechtB. N. (2009). House dust mite allergen induces asthma via toll-like receptor 4 triggering of airway structural cells. Nat. Med. 15, 410–416. 10.1038/nm.1946
27
HammadH.LambrechtB. N. (2015). Barrier epithelial cells and the control of type 2 immunity. Immunity43, 29–40. 10.1016/j.immuni.2015.07.007
28
HaraK.IijimaK.EliasM. K.SenoS.TojimaI.KobayashiT.et al. (2014). Airway uric acid is a sensor of inhaled protease allergens and initiates type 2 immune responses in respiratory mucosa. J. Immunol. 192, 4032–4042. 10.4049/jimmunol.1400110
29
HershensonM. B. (2007). Proteases and protease-activated receptors signalling: at the crossroads of acquired and innate immunity. Clin. Exp. Allergy37, 963–966. 10.1111/j.1365-2222.2007.02738.x
30
HirasawaY. (2010). Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J. Invest. Dermat.130, 614–617. 10.1038/jid.2009.257
31
HuangL.WringS. A.WoolleyJ. L.BrouwerK. R.Serabjit-SinghC.PolliJ. W. (2001). Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metabol. Disposition29, 754–760.
32
IkedaK.ShiozawaA.OnoN.KusunokiT.HirotsuM.HommaH.et al. (2013). Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil. Laryngoscope123, E1–E9. 10.1002/lary.24154
33
JacquetA. (2011). Interactions of airway epithelium with protease allergens in the allergic response. Clin. Exp. Allergy41, 305–311. 10.1111/j.1365-2222.2010.03661.x
34
KaleS. L.AgrawalK.GaurS. N.AroraN. (2017). Cockroach protease allergen induces allergic airway inflammation via epithelial cell activation. Sci Rep.7:42341. 10.1038/srep42341
35
KamijoS.TakedaH.TokuraT.SuzukiM.InuiK.HaraM.et al. (2013). IL-33–mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen–induced allergic airway inflammation. J. Immunol. 190, 4489–4499. 10.4049/jimmunol.1201212
36
KesicM. J.HernandezM.JaspersI. (2012). Airway protease/antiprotease imbalance in atopic asthmatics contributes to increased Influenza A virus cleavage and replication. Respir. Res. 13:82. 10.1186/1465-9921-13-82
37
KheradmandF.KissA.XuJ.LeeS. H.KolattukudyP. E.CorryD. B. (2002). A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J. Immunol. 169, 5904–5911. 10.4049/jimmunol.169.10.5904
38
KimD. Y.ChoS. H.TakabayashiT.SchleimerR. P. (2015). Chronic rhinosinusitis and the coagulation system. Allergy Asthma Immunol. Res. 7, 421–430. 10.4168/aair.2015.7.5.421
39
KimJ.-W.HongS. L.KimY. K.LeeC. H.MinY. G.RheeC. S. (2007). Histological and immunological features of non-eosinophilic nasal polyps. Otolaryngol. Head Neck Surg. 137, 925–930. 10.1016/j.otohns.2007.07.036
40
KouzakiH.MatsumotoK.KatoT.TojimaI.ShimizuS.ShimizuT. (2016). Epithelial cell-derived cytokines contribute to the pathophysiology of eosinophilic chronic rhinosinusitis. J. Interferon. Cytokine Res. 36, 169–179. 10.1089/jir.2015.0058
41
KouzakiH.MatsumotoK.KikuokaH.KatoT.TojimaI.ShimizuS.et al. (2017). Endogenous protease inhibitors in airway epithelial cells contribute to eosinophilic chronic rhinosinusitis. Am. J. Respir. Crit. Care Med. 195, 737–747. 10.1164/rccm.201603-0529OC
42
LambrechtB. N.HammadH. (2013). Asthma and coagulation. N. Engl. J. Med. 369, 1964–1966. 10.1056/NEJMcibr1311045
43
LanF.ZhangN.GevaertE.ZhangL.BachertC. (2016). Viruses and bacteria in Th2-biased allergic airway disease. Allergy71, 1381–1392. 10.1111/all.12934
44
MadeoJ.FrieriM. (2013). Bacterial biofilms and chronic rhinosinusitis. Allergy Asthma Proc. 34, 335–341. 10.2500/aap.2013.34.3665
45
MeadenE. R.HoggardP. G.NewtonP.TjiaJ. F.AldamD.CornforthD.et al. (2002). P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J. Antimicrob. Chemother. 50, 583–588. 10.1093/jac/dkf161
46
MendelsohnD.JeremicG.WrightE. D.RotenbergB. W. (2011). Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann. Otol. Rhinol. Laryngol. 120, 162–166. 10.1177/000348941112000304
47
MillienV. O.LuW.ShawJ.YuanX.MakG.RobertsL.et al. (2013). Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science341, 792–796. 10.1126/science.1240342
48
MoffattM. (2004). SPINK5: a gene for atopic dermatitis and asthma. Clin. Exp. Allergy34, 325–327. 10.1111/j.1365-2222.2004.01915.x
49
MortuaireG.LeroyX.GenglerI.ChevalierD.PrinL.PicryA. (2015). Histopathological classification of refractory chronic rhinosinusitis with nasal polyps. Histol. Histopathol. 30, 1447–1454. 10.14670/HH-11-632
50
OrlandiR. R.KingdomT. T.HwangP. H.SmithT. L.AltJ. A.BaroodyF. M.et al. (2016). International consensus statement on allergy and rhinology: rhinosinusitis. Int. Forum Allergy Rhinol. 6(Suppl. 1), S22–S209. 10.1002/alr.21695
51
OuJ.WangJ.XuY.TaoZ. Z.KongY. G.ChenS.-M.et al. (2014). Staphylococcus aureus superantigens are associated with chronic rhinosinusitis with nasal polyps: a meta-analysis. Eur. Arch. Otorhinolaryngol. 271, 2729–2736. 10.1007/s00405-014-2955-0
52
PerloffM. D.von MoltkeL. L.FaheyJ. M.DailyJ. P.GreenblattD. J. (2000). Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. Aids14, 1287–1289. 10.1097/00002030-200006160-00034
53
PfefferP. E.CorriganC. J. (2017). An imbalance between proteases and endogenous protease inhibitors in eosinophilic airway disease. Am. J. Respir. Crit. Care Med.195, 707–708. 10.1164/rccm.201610-2020ED
54
ReedC. E.KitaH. (2004). The role of protease activation of inflammation in allergic respiratory diseases. J. Allergy Clin. Immunol. 114, 997–1008. 10.1016/j.jaci.2004.07.060
55
RunswickS.MitchellT.DaviesP.RobinsonC.GarrodD. R. (2007). Pollen proteolytic enzymes degrade tight junctions. Respirology12, 834–842. 10.1111/j.1440-1843.2007.01175.x
56
SachseF.BeckerK.Von EiffC.MetzeD.RudackC. (2010). Staphylococcus aureus invades the epithelium in nasal polyposis and induces IL-6 in nasal epithelial cells in vitro. Allergy65, 1430–1437. 10.1111/j.1398-9995.2010.02381.x
57
SchleimerR. P. (2017). Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu. Rev. Pathol. 12, 331–357. 10.1146/annurev-pathol-052016-100401
58
SchleimerR. P.BerdnikovsS. (2017). Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. J. Allergy Clin. Immunol. 139, 1752–1761. 10.1016/j.jaci.2017.04.010
59
ShahS. A.IshinagaH.TakeuchiK. (2016). Pathogenesis of eosinophilic chronic rhinosinusitis. J. Immunol. 13:11. 10.1186/s12950-016-0121-8
60
ShikaniA. H.SidhayeV. K.BasarabaR. J.ShikaniH. J.AlqudahM. A.KirkN.et al. (2014). Mucosal expression of aquaporin 5 and epithelial barrier proteins in chronic rhinosinusitis with and without nasal polyps. Am. J. Otolaryngol. 35, 377–383. 10.1016/j.amjoto.2013.11.011
61
ShimizuS.GabazzaE. C.OgawaT.TojimaI.HoshiE. H.Kouzakiet al. (2011). Role of thrombin in chronic rhinosinusitis-associated tissue remodeling. Am. J. Rhinol. Allergy25, 7–11. 10.2500/ajra.2011.25.3535
62
ShinS.-H.LeeY. H. (2010). Airborne fungi induce nasal polyp epithelial cell activation and toll-like receptor expression. Int. Arch. Allergy Immunol. 153, 46–52. 10.1159/000301578
63
ShinS.-H.LeeY. H.JeonC. H. (2006). Protease-dependent activation of nasal polyp epithelial cells by airborne fungi leads to migration of eosinophils and neutrophils. Acta Otolaryngol. 126, 1286–1294. 10.1080/00016480500395179
64
SnelgroveR. J.GregoryL. G.PeiróT.AktharS.CampbellG. A.WalkerS. A.et al. (2014). Alternaria-derived serine protease activity drives IL-33–mediated asthma exacerbations. J. Allergy Clin. Immunol. 134, 583–592.e6. 10.1016/j.jaci.2014.02.002
65
SokolC. L.BartonG. M.FarrA. G.MedzhitovR. (2008). A mechanism for the initiation of the Th2 response by an allergen. Nat. Immunol. 9, 310–318. 10.1038/ni1558
66
StentzelS.TeufelbergerA.NordengrünM.KolataJ.SchmidtF.van CrombruggenK.et al. (2017). Staphylococcal serine protease–like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus. J. Allergy Clin. Immunol. 139, 492–500.e8. 10.1016/j.jaci.2016.03.045
67
StevensW. W.PetersA. T.HirschA. G.NordbergC. M.SchwartzB. S.MercerD. G.et al. (2017). Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract. 5, 1061–1070.e3. 10.1016/j.jaip.2016.12.027
68
TaV.WhiteA. A. (2015). Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract. 3, 711–718. 10.1016/j.jaip.2015.03.001
69
TaiH. Y.TamM.ChouH.PengH. J.SuS. N.PerngD. W.et al. (2006). Pen ch 13 allergen induces secretion of mediators and degradation of occludin protein of human lung epithelial cells. Allergy61, 382–388. 10.1111/j.1398-9995.2005.00958.x
70
TakaiT.IkedaS. (2011). Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases. Allergol Int. 60, 25–35. 10.2332/allergolint.10-RAI-0273
71
TeufelbergerA. R.NordengrünM.BraunH.MaesT.De GroveK.HoltappelsG.et al. (2017). The IL-33/ST2 axis is crucial in type 2 airway responses induced by the Staphylococcus aureus-derived serine protease-like protein D. J. Allergy Clin. Immunol. [Epub ahead of print]. 10.1016/j.jaci.2017.05.004
72
TieuD. D.KernR. C.SchleimerR. P. (2009). Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis. J. Allergy Clin. Immunol. 124, 37–42. 10.1016/j.jaci.2009.04.045
73
TipirneniK. E.WoodworthB. A. (2017). Medical and surgical advancements in the management of cystic fibrosis chronic rhinosinusitis. Curr. Otorhinolaryngol. Rep. 5, 24–34. 10.1007/s40136-017-0139-3
74
TomassenP.VandeplasG.Van ZeleT.CardellL. O.ArebroJ.OlzeH.et al. (2016). Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J. Allergy Clin. Immunol. 137, 1449–1456.e4. 10.1016/j.jaci.2015.12.1324
75
TosunF.ArslanH. H.KarsliogluY.DeveciM. S.DurmazA. (2010). Relationship between postoperative recurrence rate and eosinophil density of nasal polyps. Ann. Otol. Rhinol. Laryngol. 119, 455–459. 10.1177/000348941011900705
76
Van ZeleT.ClaeysS.GevaertP.Van MaeleG.HoltappelsG.Van CauwenbergeP.et al. (2006). Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy61, 1280–1289. 10.1111/j.1398-9995.2006.01225.x
77
VermaS.DixitR.PandeyK. C. (2016). Cysteine proteases: modes of activation and future prospects as pharmacological targets. Front. Pharmacol.7:107. 10.3389/fphar.2016.00107
78
WanH.WintonH. L.SoellerC.ToveyE. R.GruenertD. C.ThompsonP. J.et al. (1999). Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J. Clin. Invest. 104, 123–133. 10.1172/JCI5844
79
WanH.WintonH. L.SoellerC.TaylorG. W.GruenertD. C.ThompsonP. J.et al. (2001). The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin. Exp. Allergy31, 279–294. 10.1046/j.1365-2222.2001.00970.x
80
WuD.LiL.ZhangM.WangJ.WeiY. (2017). Two inflammatory phenotypes of nasal polyps and comorbid asthma. Ann. Allergy Asthma Immunol. 118, 318–325. 10.1016/j.anai.2016.12.018
81
WuD.WangJ.ZhangM. (2016). Altered Th17/Treg ratio in nasal polyps with distinct cytokine profile: association with patterns of inflammation and mucosal remodeling. Medicine95:e2998. 10.1097/MD.000000000000299
82
WynnR.Har-ElG. (2004). Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope114, 811–813. 10.1097/00005537-200405000-00004
83
ZastreJ. A.ChanG. N.RonaldsonP. T.RamaswamyM.CouraudP. O.RomeroI. A.et al. (2009). Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 87, 1023–1036. 10.1002/jnr.21898
84
ZhangN.Van ZeleT.Perez-NovoC.Van BruaeneN.HoltappelsG.DeRuyckN.et al. (2008). Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J. Allergy Clin. Immunol. 122, 961–968. 10.1016/j.jaci.2008.07.008
85
ZhangY.BenetL. Z. (1998). Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res. 15, 1520–1524. 10.1023/A:1011990730230
Summary
Keywords
chronic rhinosinusitis, nasal polyps, eosinophil, protease, epithelium
Citation
Wu D, Wei Y and Bleier BS (2018) Emerging Role of Proteases in the Pathogenesis of Chronic Rhinosinusitis with Nasal Polyps. Front. Cell. Infect. Microbiol. 7:538. doi: 10.3389/fcimb.2017.00538
Received
04 October 2017
Accepted
26 December 2017
Published
12 January 2018
Volume
7 - 2017
Edited by
Richard George Douglas, University of Auckland, New Zealand
Reviewed by
Simon Carney, Flinders University, Australia; Eui-Cheol Shin, KAIST, South Korea
Updates
Copyright
© 2018 Wu, Wei and Bleier.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Benjamin S. Bleier benjamin_bleier@meei.harvard.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.